201 related articles for article (PubMed ID: 28144709)
1. Glucagon increase after chronic AT
Mildner M; Müller-Fielitz H; Stölting I; Jöhren O; Steckelings M; Raasch W
Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):505-518. PubMed ID: 28144709
[TBL] [Abstract][Full Text] [Related]
2. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Harada N; Shimozawa N; Okajima K
Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
[TBL] [Abstract][Full Text] [Related]
3. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
4. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
[TBL] [Abstract][Full Text] [Related]
6. Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.
Müller-Fielitz H; Markert A; Wittmershaus C; Pahlke F; Jöhren O; Raasch W
Naunyn Schmiedebergs Arch Pharmacol; 2011 Apr; 383(4):373-84. PubMed ID: 21287150
[TBL] [Abstract][Full Text] [Related]
7. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries.
Thorup C; Kornfeld M; Goligorsky MS; Moore LC
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S220-4. PubMed ID: 9892167
[TBL] [Abstract][Full Text] [Related]
8. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
[TBL] [Abstract][Full Text] [Related]
9. Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.
Tallam LS; Jandhyala BS
Clin Exp Pharmacol Physiol; 2001; 28(5-6):433-40. PubMed ID: 11380518
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptors.
Ardaillou R
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S30-9. PubMed ID: 9892138
[TBL] [Abstract][Full Text] [Related]
12. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Liang B; Leenen FH
J Cardiovasc Pharmacol; 2008 May; 51(5):457-66. PubMed ID: 18418273
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Takahashi S; Uemura H; Seeni A; Tang M; Komiya M; Long N; Ishiguro H; Kubota Y; Shirai T
Prostate; 2012 Oct; 72(14):1559-72. PubMed ID: 22430461
[TBL] [Abstract][Full Text] [Related]
14. The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat.
Champion HC; Bivalacqua TJ; Lambert DG; McNamara DB; Kadowitz PJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S95-7. PubMed ID: 9892147
[TBL] [Abstract][Full Text] [Related]
15. AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.).
Barauna VG; Mantuan PR; Magalhães FC; Campos LC; Krieger JE
Biochem Biophys Res Commun; 2013 Nov; 441(4):713-9. PubMed ID: 24211212
[TBL] [Abstract][Full Text] [Related]
16. Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system.
Gammelgaard I; Wamberg S; Bie P
Acta Physiol (Oxf); 2006 Oct; 188(2):129-38. PubMed ID: 16948800
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes.
Zhou J; Xu X; Liu JJ; Lin YX; Gao GD
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1191-8. PubMed ID: 17880376
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
Kakuta H; Sudoh K; Sasamata M; Yamagishi S
Int J Clin Pharmacol Res; 2005; 25(1):41-6. PubMed ID: 15864875
[TBL] [Abstract][Full Text] [Related]
19. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.
Schuchard J; Winkler M; Stölting I; Schuster F; Vogt FM; Barkhausen J; Thorns C; Santos RA; Bader M; Raasch W
Br J Pharmacol; 2015 Aug; 172(15):3764-78. PubMed ID: 25906670
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
